Scope
Reference
DACPM2025-41
Description
Procurement of Ravulizumab IV Infusion.
Contract 1. Ravulizumab IV Infusion
Supplier
Contract value
- £1,200,000 excluding VAT
- £1,200,000 including VAT
Above the relevant threshold
Earliest date the contract will be signed
3 October 2025
Contract dates (estimated)
- 3 October 2025 to 30 September 2027
- 1 year, 11 months, 28 days
Main procurement category
Goods
CPV classifications
- 33600000 - Pharmaceutical products
Contract locations
- UKN - Northern Ireland
Other information
Conflicts assessment prepared/revised
Yes
Procedure
Procedure type
Direct award
Direct award justification
Single supplier - intellectual property or exclusive rights
These are branded patent protected medicines that are essential to patient care and are available from only one economic operator. The absence of competition is not a result of the artificial narrowing of the parameters of the procurement.
Supplier
ALEXION PHARMA UK LIMITED
- Companies House: 05970106
- Public Procurement Organisation Number: PQTX-1761-VLYY
1 Francis Crick Avenue
Cambridge
CB2 0AA
United Kingdom
Email: UKMarketAccess@alexion.com
Region: UKH12 - Cambridgeshire CC
Contract 1. Ravulizumab IV Infusion
Contracting authority
Belfast Health & Social Care Trust
- Public Procurement Organisation Number: PLQJ-5727-JCLR
Trust Headquarters, 2nd Floor, Non Clinical Support Building, Royal Victoria Hospital
Belfast
BT12 6BA
United Kingdom
Region: UKN06 - Belfast
Organisation type: Public authority - central government
Devolved regulations that apply: Northern Ireland